IE56026B1
(en)
*
|
1982-10-19 |
1991-03-27 |
Cetus Corp |
Cysteine-depleted muteins of biologically active proteins
|
US5288852A
(en)
*
|
1984-03-06 |
1994-02-22 |
Dainippon Pharmaceutical Co., Ltd. |
Human tumor necrosis factor polypeptides
|
US5342614A
(en)
*
|
1984-12-21 |
1994-08-30 |
Otsuka Pharmaceutical Co., Ltd. |
Method of treating arthritus or inflammation with IL-1β or derivatives thereof
|
US6107465A
(en)
*
|
1984-12-21 |
2000-08-22 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1β and derivatives thereof and drugs
|
US5516896A
(en)
*
|
1985-02-25 |
1996-05-14 |
Zymogenetics, Inc. |
Biologically active B-chain homodimers
|
US5244806A
(en)
*
|
1985-08-26 |
1993-09-14 |
Eli Lilly And Company |
DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
|
US5859208A
(en)
*
|
1988-07-06 |
1999-01-12 |
Fiddes; John C. |
Human basic fibroblast growth factor analog
|
US5081021A
(en)
*
|
1986-02-04 |
1992-01-14 |
Mizuno Den Ichi |
DNA encoding HTNF variants exhibiting enhanced activity
|
US5008374A
(en)
*
|
1986-03-14 |
1991-04-16 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1α derivatives and drugs
|
US5900476A
(en)
*
|
1986-05-30 |
1999-05-04 |
The Scripps Research Institute |
Therapeutic domains of van Willebrand factor
|
EP0585957A1
(de)
*
|
1986-08-06 |
1994-03-09 |
Ajinomoto Co., Inc. |
Rekombinanter B-Zell-Differenzierungsfaktor
|
US5681934A
(en)
*
|
1986-09-30 |
1997-10-28 |
Board Of Regents, The University Of Texas System |
47-kilodalton antigen of Treponema pallidum
|
US7049131B1
(en)
*
|
1987-02-12 |
2006-05-23 |
Genentech, Inc. |
Methods and deoxyribonucleic acid for the preparation of tissue factor protein
|
US6994988B1
(en)
|
1987-02-12 |
2006-02-07 |
Genetech, Inc. |
Methods and deoxyribonucleic acid for the preparation of tissue factor protein
|
US5852177A
(en)
*
|
1987-02-24 |
1998-12-22 |
Takeda Chemical Industries, Ltd. |
Basic fibroblast growth factor (bFGF) muteins
|
AU1346488A
(en)
*
|
1987-02-26 |
1988-09-26 |
Cetus Corporation |
Arginine-depleted human tumor necrosis factor
|
ZA884012B
(en)
*
|
1987-06-04 |
1989-02-22 |
Zymogenetics Inc |
Tissue plasminogen activator analogs having modified growth factor domains
|
DE68929273T2
(de)
*
|
1988-08-24 |
2001-07-05 |
American Cyanamid Co |
Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
|
DE3907244A1
(de)
*
|
1989-03-07 |
1990-09-13 |
Knoll Ag |
Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6207798B1
(en)
*
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
FR2651130B1
(fr)
*
|
1989-08-23 |
1991-12-13 |
Roussel Uclaf |
Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
|
EP0447523A4
(en)
*
|
1989-10-10 |
1991-11-27 |
Amgen Inc. |
Compositions and methods for treating or preventing infections in canine and feline animals
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
RU2212411C2
(ru)
*
|
1989-10-16 |
2003-09-20 |
Эмджен Инк. |
Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US7144731B2
(en)
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US6566098B1
(en)
*
|
1990-09-14 |
2003-05-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
DNA encoding truncated hepatocyte growth factor variants
|
JPH05255393A
(ja)
*
|
1990-09-21 |
1993-10-05 |
Ishihara Sangyo Kaisha Ltd |
ポリペプチド
|
EP0477791B1
(de)
*
|
1990-09-21 |
1996-08-07 |
Ishihara Sangyo Kaisha, Ltd. |
Polypeptid
|
DE69119869T2
(de)
*
|
1990-11-23 |
1996-12-12 |
American Cyanamid Co |
Chimeres Fibroblasten-Wachstumsfaktor
|
US6833354B1
(en)
*
|
1990-12-19 |
2004-12-21 |
Kaken Pharmaceutical Co., Ltd. |
Agent for the treatment of bone diseases
|
CA2107100A1
(en)
*
|
1991-03-27 |
1992-09-28 |
Zaverio M. Ruggeri |
Therapeutic fragments of von willebrand factor
|
JP3303211B2
(ja)
*
|
1991-04-26 |
2002-07-15 |
武田薬品工業株式会社 |
bFGFムテインおよびその製造法
|
US5847086A
(en)
*
|
1991-06-20 |
1998-12-08 |
Centeon L.L.C. |
Therapeutic fragments of von Willebrand factor
|
WO1993000107A1
(en)
*
|
1991-06-20 |
1993-01-07 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Therapeutic fragments of von willebrand factor
|
ZA924674B
(en)
*
|
1991-07-02 |
1993-04-28 |
Imclone Systems Inc |
Cysteine depleted il-6 mutein
|
US5248604A
(en)
*
|
1991-07-22 |
1993-09-28 |
Bio-Technology General Corp. |
Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
GB9204439D0
(en)
*
|
1992-02-27 |
1992-04-15 |
Fujisawa Pharmaceutical Co |
A new cephalosporin c acylase
|
US5444151A
(en)
*
|
1992-05-15 |
1995-08-22 |
Ludwig Institute For Cancer Research |
Platelet derived growth factor antagonists
|
US5326695A
(en)
*
|
1992-05-15 |
1994-07-05 |
Ludwig Institute For Cancer Research |
Platelet derived growth factor agonists
|
US5349056A
(en)
*
|
1992-10-09 |
1994-09-20 |
Regeneron Pharmaceuticals |
Modified ciliary neurotrophic factors
|
US5420019A
(en)
*
|
1993-02-02 |
1995-05-30 |
Xoma Corporation |
Stable bactericidal/permeability-increasing protein muteins
|
DE69434332T2
(de)
*
|
1993-11-12 |
2006-02-02 |
Gilead Sciences, Inc., Foster City |
Thrombin mutanten
|
US7060484B1
(en)
|
1993-11-12 |
2006-06-13 |
Gilead Sciences, Inc. |
Polypeptides and coagulation therapy
|
US20030220233A1
(en)
|
1994-01-24 |
2003-11-27 |
Neorx Corporation |
Radiolabeled annexins
|
US5968477A
(en)
*
|
1994-01-24 |
1999-10-19 |
Neorx Corporation |
Radiolabeled annexin conjugates with hexose and a chelator
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
EP0785948B1
(de)
*
|
1994-10-13 |
2003-04-16 |
Amgen Inc., |
Analogen des keratinozytenwachstumfaktors
|
US6818220B1
(en)
|
1994-11-14 |
2004-11-16 |
Licentia Ltd. |
Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US7423125B2
(en)
*
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
US20030202980A1
(en)
*
|
1995-12-29 |
2003-10-30 |
Caplan Michael J. |
Methods and reagents for decreasing clinical reaction to allergy
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
TW555765B
(en)
*
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US20030144202A1
(en)
*
|
1996-10-15 |
2003-07-31 |
Amgen Inc. |
Uses of keratinocyte growth factor-2
|
US6743422B1
(en)
|
1996-10-15 |
2004-06-01 |
Amgen, Inc. |
Keratinocyte growth factor-2 products
|
EP0942740B1
(de)
|
1996-12-06 |
2003-08-27 |
Amgen Inc., |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
DE69738841D1
(de)
|
1996-12-23 |
2008-08-28 |
Immunex Corp |
Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
|
EP0966480A2
(de)
|
1997-01-30 |
1999-12-29 |
The University Of Virginia Patent Foundation |
Cystein-reduzierte peptide, welche durch a3-limitierte zytotoxische lymphozyten erkannt werden, sowie anwendungen
|
US7125714B2
(en)
*
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
KR100496063B1
(ko)
*
|
1997-04-15 |
2005-06-21 |
산쿄 가부시키가이샤 |
신규단백질 및 그 제조방법
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
DK0975754T4
(en)
|
1997-04-16 |
2016-03-21 |
Amgen Inc |
Osteoprotegerin binding proteins and their receptors
|
AU7383298A
(en)
*
|
1997-05-13 |
1998-12-08 |
Regents Of The University Of California, The |
Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
|
US7723473B2
(en)
*
|
1997-06-19 |
2010-05-25 |
St. Louis University |
Peptide antagonists of TGF-beta family members and therapeutic uses thereof
|
ATE305510T1
(de)
|
1997-12-17 |
2005-10-15 |
Immunex Corp |
Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
|
US8101349B2
(en)
|
1997-12-23 |
2012-01-24 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells and their methods of use II
|
EP1051494B1
(de)
|
1998-01-31 |
2009-04-29 |
The University of Arkansas |
Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
|
US7879977B2
(en)
|
1998-01-31 |
2011-02-01 |
University Of Arkansas |
Methods and reagents for decreasing clinical reaction to allergy
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US6476211B1
(en)
*
|
1998-07-16 |
2002-11-05 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
AU762392B2
(en)
*
|
1998-07-16 |
2003-06-26 |
Arca Biopharma, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6387645B1
(en)
|
1998-07-16 |
2002-05-14 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6447771B1
(en)
*
|
1999-03-19 |
2002-09-10 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6979442B1
(en)
|
1998-08-17 |
2005-12-27 |
Pfizer Inc. |
Stabilized protein compositions
|
EP2123292B1
(de)
|
1998-09-03 |
2016-05-04 |
Novartis Vaccines and Diagnostics, Inc. |
FGF-2 angiogenische wirksame Einheitdosis und Verfahren zu ihrer Verwendung
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6696063B1
(en)
*
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US6350447B1
(en)
|
1999-01-29 |
2002-02-26 |
Hyseq, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6780977B1
(en)
|
1999-01-29 |
2004-08-24 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6899875B1
(en)
|
1999-01-29 |
2005-05-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6783959B1
(en)
|
1999-01-29 |
2004-08-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
JP2002541804A
(ja)
*
|
1999-04-09 |
2002-12-10 |
カイロン コーポレイション |
分泌ヒトタンパク質
|
US6514729B1
(en)
|
1999-05-12 |
2003-02-04 |
Xencor, Inc. |
Recombinant interferon-beta muteins
|
US6703221B1
(en)
*
|
1999-08-19 |
2004-03-09 |
Chiron Corporation |
Notch receptor ligands and uses thereof
|
US6825333B1
(en)
|
1999-08-20 |
2004-11-30 |
Chiron Corporation |
EGFH2 genes and gene products
|
CA2393688A1
(en)
*
|
1999-12-09 |
2001-06-14 |
Chiron Corporation |
Method for administering a cytokine to the central nervous system and the lymphatic system
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US20050063994A1
(en)
*
|
2000-04-06 |
2005-03-24 |
Caplan Michael J. |
Methods and reagents for decreasing clinical reaction to allergy
|
US8246945B2
(en)
*
|
2000-04-06 |
2012-08-21 |
University Of Arkansas |
Methods and reagents for decreasing clinical reaction to allergy
|
DK1272213T3
(da)
*
|
2000-04-06 |
2006-07-10 |
Seer Pharmaceuticals Llc |
Mikrobielt afgivelsessystem
|
JP2003530838A
(ja)
*
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2001085208A2
(en)
*
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
US7700359B2
(en)
*
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
PT1370684E
(pt)
|
2000-06-15 |
2008-09-08 |
Novartis Vaccines & Diagnostic |
Polinucleótidos ligados ao cancro do colon
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
US20030039647A1
(en)
*
|
2000-07-14 |
2003-02-27 |
Christoph Reinhard |
Tetraspan protein and uses thereof
|
AU2002227365A1
(en)
|
2000-12-07 |
2002-06-18 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
WO2002052047A2
(en)
*
|
2000-12-22 |
2002-07-04 |
Mergen Ltd. |
Methods for identifying g-protein coupled receptors associated with diseases
|
US7094409B2
(en)
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081640A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2830887C
(en)
|
2001-06-05 |
2016-11-29 |
Curevac Gmbh |
Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
|
WO2003015697A2
(en)
*
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
EP1436385A4
(de)
*
|
2001-09-14 |
2005-12-14 |
Invitrogen Corp |
Dna-polymerasen und mutanten davon
|
WO2003030821A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US20060275747A1
(en)
*
|
2001-12-07 |
2006-12-07 |
Hardy Stephen F |
Endogenous retrovirus up-regulated in prostate cancer
|
US20070037147A1
(en)
*
|
2001-12-07 |
2007-02-15 |
Pablo Garcia |
Endogenous retrovirus polypeptides linked to oncogenic transformation
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
IL147414A0
(en)
|
2001-12-31 |
2002-08-14 |
Yeda Res & Dev |
Ifnar2 mutants, their production and use
|
AU2003218350A1
(en)
*
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
JP4761710B2
(ja)
*
|
2002-04-05 |
2011-08-31 |
アムジェン インコーポレイテッド |
選択的opgl経路インヒビターとしてのヒト抗opgl中和抗体
|
US7585840B2
(en)
|
2002-04-10 |
2009-09-08 |
Merck Serono S.A. |
Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
KR20040107492A
(ko)
*
|
2002-04-10 |
2004-12-20 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
TWI334785B
(en)
*
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
US8518694B2
(en)
*
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
AU2003248845A1
(en)
*
|
2002-07-12 |
2004-02-02 |
The Regents Of The University Of California |
Steroidogenic factor-1 protein variants and methods of making same
|
WO2004016282A1
(en)
*
|
2002-07-19 |
2004-02-26 |
Cytos Biotechnology Ag |
Vaccine compositions containing amyloid beta1-6 antigen arrays
|
US20040175359A1
(en)
*
|
2002-11-12 |
2004-09-09 |
Desjarlais John Rudolph |
Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20040170982A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US20060210588A1
(en)
*
|
2003-03-26 |
2006-09-21 |
Cytos Biotechnology Ag |
Hiv-peptide-carrier-conjugates
|
WO2004084940A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
|
US7537767B2
(en)
*
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
JP4865540B2
(ja)
|
2003-04-08 |
2012-02-01 |
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド |
化学誘引物質に対する増大された感受性を有する幹細胞およびそれを産生および使用する方法
|
FR2853551B1
(fr)
|
2003-04-09 |
2006-08-04 |
Lab Francais Du Fractionnement |
Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
|
TWI272948B
(en)
|
2003-05-01 |
2007-02-11 |
Ares Trading Sa |
HSA-free stabilized interferon liquid formulations
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
IL158868A0
(en)
|
2003-11-13 |
2004-05-12 |
Yeda Res & Dev |
Methods of generating and using stem cells enriched with immature primitive progenitor
|
DE102004008168B4
(de)
*
|
2004-02-19 |
2015-12-10 |
Voxeljet Ag |
Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
|
EP1734988A4
(de)
*
|
2004-03-01 |
2009-08-05 |
Enzon Pharmaceuticals Inc |
Interferon-beta-polymerkonjugate
|
IL161673A0
(en)
|
2004-04-29 |
2004-09-27 |
Applied Research Systems |
Compositions and methods for therapy of chemotherapy-induced neuropathy
|
US7879320B2
(en)
*
|
2004-05-17 |
2011-02-01 |
Ares Trading S.A. |
Hydrogel interferon formulations
|
UA92146C2
(ru)
*
|
2004-06-01 |
2010-10-11 |
Эйрэс Трейдинг С.А. |
Стабилизированная жидкая композиция, которая содержит интерферон
|
JP2008500995A
(ja)
|
2004-06-01 |
2008-01-17 |
アレス トレーディング ソシエテ アノニム |
タンパク質安定化法
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
CA2583230A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
GB0424563D0
(en)
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
JP4891250B2
(ja)
*
|
2004-11-10 |
2012-03-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
脱アミドされたインターフェロンβ
|
TW200633718A
(en)
*
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
WO2006110599A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cacna1e in cancer diagnosis, detection and treatment
|
JP2008535494A
(ja)
|
2005-04-07 |
2008-09-04 |
サグレシュ ディスカバリー, インコーポレイテッド |
癌関連遺伝子(prlr)
|
US20060242012A1
(en)
*
|
2005-04-22 |
2006-10-26 |
Sumit Agarwal |
Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
|
CA2603671C
(en)
|
2005-04-26 |
2012-03-27 |
Laboratoires Serono S.A. |
Insp163 polypeptides for the treatment or prevention of cancer and arthritis
|
SG195394A1
(en)
|
2005-05-18 |
2013-12-30 |
Biofactura Inc |
Compositions and methods for metabolic selection of transfected cells
|
EP1885858A2
(de)
*
|
2005-05-19 |
2008-02-13 |
Bayer Schering Pharma Aktiengesellschaft |
Behandlung von krankheiten unter anwendung eines verbesserten regulierten expressionssystems
|
DOP2006000117A
(es)
*
|
2005-05-19 |
2007-11-30 |
Schering Ag |
Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
|
US20080076729A1
(en)
*
|
2005-05-19 |
2008-03-27 |
Schering Aktiengesellachaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
US20070179113A1
(en)
*
|
2005-05-19 |
2007-08-02 |
Schering Aktiengesellachaft |
GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
|
ATE557038T1
(de)
|
2005-06-03 |
2012-05-15 |
Ares Trading Sa |
Herstellung von rekombinantem il-18 bindendem protein
|
EP1891088B1
(de)
*
|
2005-06-10 |
2011-10-19 |
Ares Trading S.A. |
Verfahren zur reinigung eines il-18-bindenden proteins
|
WO2007014156A2
(en)
*
|
2005-07-21 |
2007-02-01 |
Buck Institute For Age Research |
Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
|
US20070026463A1
(en)
*
|
2005-07-28 |
2007-02-01 |
Wyeth |
Compositions and methods of mutant Nogo-66 domain proteins
|
JP2009502173A
(ja)
*
|
2005-07-29 |
2009-01-29 |
ノバルティス アーゲー |
インビトロでのタンパク質折りたたみのための方法およびシステム
|
SG155183A1
(en)
|
2005-08-26 |
2009-09-30 |
Ares Trading Sa |
Process for the preparation of glycosylated interferon beta
|
EP1760092A1
(de)
|
2005-08-26 |
2007-03-07 |
Applied Research Systems ARS Holding N.V. |
System für Screening von Zellen mit hoher Expression von einem interessierenden Protein
|
KR20080050591A
(ko)
*
|
2005-09-01 |
2008-06-09 |
아레스 트레이딩 에스.에이. |
시신경염 치료
|
ES2336575T3
(es)
|
2005-09-22 |
2010-04-14 |
Biocompatibles Uk Limited |
Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
|
JP2009537605A
(ja)
|
2006-05-24 |
2009-10-29 |
メルク セローノ ソシエテ アノニム |
多発性硬化症を治療するためのクラドリビン・レジメン
|
WO2008001370A2
(en)
|
2006-06-28 |
2008-01-03 |
Yeda Research And Development Co. Ltd |
Caspase-8 and inflammation, infection and wound healing
|
EP2046110A4
(de)
*
|
2006-07-07 |
2010-10-27 |
Univ Washington State |
Gene, die für die chavicol/eugenol-synthase aus dem kreosotbusch larrea tridentata kodieren
|
EP2469282A1
(de)
*
|
2006-09-08 |
2012-06-27 |
University of Oxford |
Klinische Diagnose von Leberfibrose mithilfe einer neuartigen Tafel von menschlichen Serumprotein-Biomarkern
|
US20100028297A1
(en)
*
|
2006-12-19 |
2010-02-04 |
Stewart Edward J |
Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
|
WO2008125222A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Bayer Schering Pharma Aktiengesellschaft |
New modulation molecules for an improved regulated expression system
|
EP2076533B1
(de)
*
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modifizierte interferon-beta-polypeptide und ihre verwendungen
|
US8946201B2
(en)
*
|
2007-08-27 |
2015-02-03 |
Saint Louis University |
Methods for inhibiting TGF-β
|
US8273561B2
(en)
*
|
2007-10-05 |
2012-09-25 |
Nuron Biotech, Inc. |
High pressure treatment of aggregated interferons
|
DK2234645T3
(da)
*
|
2007-12-20 |
2012-07-09 |
Merck Serono Sa |
Peg-interferon-beta-formuleringer
|
IL189408A0
(en)
|
2008-02-10 |
2009-02-11 |
Yeda Res & Dev |
Siva3, its preparation and pharmaceutical compositions containing it
|
EP2257628A4
(de)
*
|
2008-03-04 |
2011-11-02 |
Univ Washington State |
Zusammensetzungen und verfahren zur differentiellen regulation der ungesättigtkeit von fettsäuren in membranlipiden und samenöl
|
PL2288715T3
(pl)
|
2008-04-11 |
2015-03-31 |
Merrimack Pharmaceuticals Inc |
Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
|
BRPI0910686A2
(pt)
|
2008-04-21 |
2015-09-29 |
Tissue Regeneration Therapeutics Inc |
células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
|
WO2010033507A1
(en)
*
|
2008-09-16 |
2010-03-25 |
St. Louis University |
Method of enhancing tgf-beta signalling
|
BRPI0921586A2
(pt)
|
2008-11-18 |
2019-09-24 |
Merrimack Pharmaceuticals Inc |
articuladores de albumina de soro humana e conjugados destes
|
US9074005B2
(en)
*
|
2009-01-02 |
2015-07-07 |
Washington State University |
Compositions and methods for modulating plant disease resistance and immunity
|
CN201397956Y
(zh)
*
|
2009-03-23 |
2010-02-03 |
富士康(昆山)电脑接插件有限公司 |
电连接器组件
|
JP5813630B2
(ja)
*
|
2009-05-14 |
2015-11-17 |
ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード |
微量ヒト血漿タンパク質バイオマーカーの新規なパネルを使用した肝線維症の臨床診断
|
EP2440251A4
(de)
|
2009-06-09 |
2013-01-16 |
Defyrus Inc |
Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
|
US20110016548A1
(en)
*
|
2009-07-16 |
2011-01-20 |
University Of Southern California |
Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA3162352A1
(en)
|
2010-10-01 |
2012-04-05 |
Modernatx, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
EP2694550B1
(de)
|
2011-04-01 |
2019-11-27 |
Universität Stuttgart |
Rekombinante polypeptidmitglieder der tnf-ligandenfamilien mit antikörperbindungsdomäne und verwendungen dafür
|
ES2563737T3
(es)
|
2011-05-20 |
2016-03-16 |
Ares Trading S.A. |
Composiciones de IFN-beta, métodos de preparación y usos de las mismas
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
EP2791160B1
(de)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modifizierte mrna zusammensetzungen
|
EP2832856A4
(de)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
Anti-lamp5-antikörper und verwendung davon
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
AU2013243946A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
EP2920212A4
(de)
*
|
2012-11-15 |
2016-07-27 |
Esperance Pharmaceuticals Inc |
Fusionskonstrukte aus dem follikelstimulierenden hormon (fsh) und einer lytischen domäne sowie verfahren zur herstellung und verwendung davon
|
LT2922554T
(lt)
|
2012-11-26 |
2022-06-27 |
Modernatx, Inc. |
Terminaliai modifikuota rnr
|
DK2953634T3
(da)
|
2013-02-07 |
2021-08-30 |
Massachusetts Gen Hospital |
Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
|
EP2971165A4
(de)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
Entfernung von dna-fragmenten in mrna-herstellungsverfahren
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
JP6941561B2
(ja)
|
2014-10-09 |
2021-09-29 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
免疫障害を処置するための複数の可変il−2用量レジメン
|
CN108929383B
(zh)
*
|
2017-05-26 |
2021-10-15 |
阿思科力(苏州)生物科技有限公司 |
重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
|
WO2023122716A1
(en)
|
2021-12-22 |
2023-06-29 |
Vanderbilt University |
Next generation transpososomes
|